Skip to main content
Clinical Trials/NCT07519200
NCT07519200
Not yet recruiting
Not Applicable

Sexual Health and Rehabilitation for Women With Metastatic Breast Cancer (SHARE-MC): An Educational Intervention

Dana-Farber Cancer Institute1 site in 1 country96 target enrollmentStarted: September 18, 2026Last updated:

Overview

Phase
Not Applicable
Status
Not yet recruiting
Enrollment
96
Locations
1
Primary Endpoint
Female Sexual Function Index (FSFI) Full-scale Score Change from Baseline

Overview

Brief Summary

This trial will evaluate the SHARE-MC educational intervention designed to address sexual health needs and related adjustment in women with metastatic breast cancer.

Detailed Description

This is a Phase II proof-of-concept investigational study evaluating the SHARE-MC educational intervention designed to address sexual health needs and related adjustment in women with metastatic breast cancer. Participants will be randomized 2:1 to receive either a group education session, or an individual self-management session. the SHARE MC intervention or enhanced usual care.

The research study procedures include: screening for eligibility, questionnaires, video conference, educational session, and coaching (as applicable).

It is expected that about 96 women will take part in this study. About 64 women will receive the group education session and about 32 will receive the individual self-management session.

Participation in this research study is expected to last about 16 weeks.

Study Design

Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel
Primary Purpose
Supportive Care
Masking
None

Eligibility Criteria

Ages
18 Years to — (Adult, Older Adult)
Sex
Female
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Women diagnosed with metastatic breast cancer
  • Functionally appropriate to participate in the intervention, as assessed by 3 functional assessment items from the EQ-5D (see Eligibility Screening, Appendix A)
  • Bothered by significant sexual dysfunction as evidenced by a Female Sexual Functioning Index (FSFI) score of ≤
  • (See Eligibility Screening, Appendix A)
  • Ability to read and write in English
  • Regular access to the internet

Exclusion Criteria

  • Diagnosis of any cancer prior to age 18
  • Has never been sexually active
  • Prior participation in Dr. Bober's sexual health research studies or workshops; or previous appointments with Dr. Bober through the DFCI Sexual Health Program.
  • Any impairment (e.g., hearing, visual, cognitive) that interferes with the ability to complete all study procedures independently

Arms & Interventions

Group Education

Experimental

64 participants will complete the following:

  • Baseline visit
  • 3-hour intervention session - educational modules
  • 4-week coaching phone call
  • 8- and 16-week follow-up assessment calls
  • A subset of participants will complete qualitative interviews

Intervention: SHARE-MC (Behavioral)

Enhanced Usual Care (Individual Self-Management)

Active Comparator

32 participants will complete the following:

  • Baseline visit
  • Individual videoconference session
  • 4-week coaching phone call
  • 8-week follow-up assessment call
  • 8- and 16-week follow-up assessment calls
  • Subset of participants will complete qualitative interviews

Intervention: Informational Booklet (Other)

Outcomes

Primary Outcomes

Female Sexual Function Index (FSFI) Full-scale Score Change from Baseline

Time Frame: Up to 8 weeks

The FSFI is a well-validated 19-item instrument assessing sexual function including lubrication, orgasm, pain and satisfaction. The total sexual function score is the sum of all domain scores, ranging from 2.0 (indicating not sexually active and no desire) to 36.0. A domain score of 0.0 means there was no sexual activity during the past month. Higher scores, both for individual domains and the total score, reflect better sexual functioning.

Secondary Outcomes

  • Brief Symptom Inventory (BSI-18) Score Change from Baseline(Up to 8 weeks)

Investigators

Sponsor Class
Other
Responsible Party
Principal Investigator
Principal Investigator

Sharon Bober, Ph.D

Principal Investigator

Dana-Farber Cancer Institute

Study Sites (1)

Loading locations...

Similar Trials